About Us

Steven R. Goodman, Ph.D., served as Vice Chancellor for Research at The University of Tennessee Health Science Center (UTHSC), from June 2015 to January 2023, during which time the Institution reached its highest level of annual Grants and Contracts in its 115-year history. Dr. Goodman currently serves as a tenured Professor in the Departments of Pediatrics with a joint appointment in Physiology and supports the Dean of the UTHSC College of Medicine on mission critical Special Projects. Dr. Goodman led the creation of the Clinical Trials Network of Tennessee (CTN2) and served as the President and CEO of CTN2. He also led the creation of the Tennessee Institute of Regenerative Medicine, the Tennessee Population Health Consortium, and the UTHSC CTSI, three statewide networks.

Prior to his arrival at UTHSC Dr. Goodman was VPR , Dean of the College of Graduate Studies, and Professor at SUNY Upstate (2008-15); Department Head, Director of an Institute and Center, and Endowed Professor at UT Dallas, while being an adjunct Professor and co-Director of the NHLBI Sickle Cell Center at UTSW (2001-08); Chair, Professor and Director of the NHLBI Sickle Cell Center at U. S. Alabama (1998-2001); Center Director and Professor (Asst., Assoc., and Full) at the Milton S. Hershey Medical Center at Penn State University (1979-98). Steve did Postdoctoral Fellowships at the Harvard BioLabs (1977-79) and Dana-Farner Cancer Inst, Harvard Medical School (1976-77). He earned his PhD in Biochemistry at St. Louis Medical School (1976) and BS in Chemistry at SUNY Stony Brook (1971).

Steve is known globally for his research into the structure and function of cell structures called membrane skeletons. His laboratory worked out many of the interactions within the red blood cell membrane skeleton, including the identification of the spectrin binding protein now called ankyrin, discovered non-erythroid spectrin and first described the spectrin isoforms and their structure and functions within the diverse cells.  As Director of NHLBI Sickle Cell Centers his research into sickle cell disease led to defining the molecular basis of the irreversibly sickle cell and his proteomic studies included the initial study of the human erythrocyte proteome, changes in the Sickle Cell proteome, and led to the seminal candidate biomarkers for sickle cell severity. Dr. Goodman’s research accomplishments were made possible by over $20 million in extramural funding and led to over one hundred and seventy-five peer reviewed publications. He is a recipient of the Society of Experimental Biology and Medicine (SEBM) Distinguished Scientist Award and was elected as a 2016 American Association for the Advancement of Science (AAAS) Fellow.

Steve is a Past President of the Association of Anatomy, Cell Biology and Neurobiology Chairs (AACBNC). He has served on multiple Boards including currently the Alliance for Cell Therapy Now. The 4^th Edition of his textbook Goodman’s Medical Cell Biology became available in July 2020. Dr. Goodman currently serves on multiple editorial boards and served as Editor-in-Chief of Experimental Biology and Medicine (EBM), the journal of the Society of Experimental Biology and Medicine (SEBM) for eighteen years beginning in 2006.  As Editor-in-Chief of EBM, Dr. Goodman globalized EBM and SEBM opening offices in six continents. He also increased the scientific topics of the journal to 22 categories covering the breadth of modern biomedical research including all translational stages from T0 to T4, basic research to population health.